Active Ingredient(s): Doravirine + Lamivudine + Tenofovir Disoproxil Fumarate
FDA Approved: * August 30, 2018
Pharm Company: * MSD MERCK CO
Category: HIV / AIDS

Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[2][4] It contains doravirine, lamivudine, and tenofovir disoproxil.[5][4] It is taken by mouth.[2] In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[5][6&... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Delstrigo Oral Tablet, Film Coated
NDC: 0006-5007
Merck Sharp & Dohme Corp.